Thermo Fisher Scientific TMO
$694.76 +$17.82 (+2.63%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $694.76 0.00%
Open$669.20
Prev close$676.94
Day range$661.60 – $697.78
Volume2.09M
Market cap$257.42B
P/E (TTM)36.6
Dividend yield0.26%
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$12.14B+9.1% YoY
Operating profit$2.46B+18.7% YoY
Net profit$1.73B+6.5% YoY
Diluted EPS$4.64+8.7% YoY
Free cash flow$2.11B+15.1% YoY
Operating cash flow$2.55B
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin41.4%
Operating margin18.7%
Net margin14.9%
Return on equity13.4%
Return on assets6.5%
Return on invested capital8.3%
Current ratio1.81
Liabilities / assets51.9%
Cash & investments$6.06B
Total debt$41.37B
Net cash (debt)-$35.31B
Free cash flow / sales16.0%
Where the revenue comes from
Quarter 2026/Q2
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $12.14B | $11.99B | $11.01B | $44.56B | $12.22B |
| Total Operating Revenue | $12.14B | $11.99B | $11.01B | $44.56B | $12.22B |
| Cost of Revenue | $6.95B | $7.11B | $6.58B | $26.32B | $7.20B |
| Gross Profit | $5.19B | $4.88B | $4.43B | $18.24B | $5.01B |
| Operating Expense | $2.73B | $2.70B | $2.52B | $10.13B | $2.71B |
| Selling and Admin Expenses | $1.86B | $2.33B | $2.18B | $8.73B | $2.35B |
| Research & Development | $348.00M | $364.00M | $336.00M | $1.40B | $356.00M |
| Depreciation & Amortization & Depletion | $519.00M | – | – | – | – |
| -Depreciation & Amortization | $519.00M | – | – | – | – |
| Operating Profit | $2.46B | $2.19B | $1.91B | $8.11B | $2.30B |
| Net Non-Operating Interest Income (Expense) | -$165.00M | -$194.00M | -$121.00M | -$426.00M | -$107.00M |
| Non-Operating Interest Income | $252.00M | $207.00M | $233.00M | $993.00M | $258.00M |
| Non-Operating Interest Expense | $417.00M | $401.00M | $354.00M | $1.42B | $365.00M |
| Other Income (Expense) | -$209.00M | -$67.00M | -$58.00M | -$374.00M | -$40.00M |
| Special Income (Charges) | -$199.00M | -$98.00M | -$49.00M | -$362.00M | -$46.00M |
| -Less:Restructuring and Mergern & Acquisition | $199.00M | $98.00M | $49.00M | $362.00M | $46.00M |
| Other Non-Operating Income (Expenses) | -$10.00M | $31.00M | -$9.00M | -$25.00M | -$7.00M |
| Pretax Profit | $2.09B | $1.92B | $1.73B | $7.31B | $2.15B |
| Tax | $352.00M | $167.00M | $70.00M | $547.00M | $153.00M |
| Earnings from Equity Interest Net of Tax | -$9.00M | -$15.00M | -$8.00M | -$41.00M | -$32.00M |
| Net Profit | $1.73B | $1.74B | $1.66B | $6.72B | $1.97B |
| Profit from Continuing Operations | $1.73B | $1.74B | $1.66B | $6.72B | $1.97B |
| Minority Interests | $6.00M | $5.00M | $5.00M | $17.00M | $6.00M |
| Net Income to Parent Company | $1.72B | $1.74B | $1.65B | $6.70B | $1.96B |
| Net Income to Common Stockholders | $1.72B | $1.74B | $1.65B | $6.70B | $1.96B |
| Basic EPS | $4.65 | $4.68 | $4.44 | $17.77 | $5.22 |
| Diluted EPS | $4.64 | $4.68 | $4.43 | $17.74 | $5.21 |
| Dividend Per Share | $0.47 | $0.47 | $0.47 | $1.72 | $0.43 |
| Gain on Sale of Security | – | – | – | $13.00M | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $114.23B | $113.17B | $113.28B | $110.34B | $110.34B |
| Total Current Assets | $25.62B | $23.37B | $22.32B | $28.71B | $28.71B |
| Cash and Cash Equivalents & Short-Term Investments | $6.06B | $4.06B | $3.26B | $10.11B | $10.11B |
| -Cash and Cash Equivalents | $5.46B | $4.06B | $3.25B | $9.85B | $9.85B |
| -Short Term Investments | $600.00M | $0.00 | $2.00M | $253.00M | $253.00M |
| Receivables | $9.63B | $11.14B | $10.89B | $10.57B | $10.57B |
| -Accounts Receivable | $9.63B | $9.45B | $9.20B | $8.90B | $8.90B |
| Inventory | $5.64B | $5.63B | $5.50B | $5.43B | $5.43B |
| Other Current Assets | $4.29B | $2.54B | $2.68B | $2.61B | $2.61B |
| Total Non-Current Assets | $88.62B | $89.81B | $90.96B | $81.64B | $81.64B |
| Net PPE | $10.58B | $10.76B | $10.66B | $10.57B | $10.57B |
| Goodwill and Other Intangible Assets | $72.34B | $73.44B | $74.33B | $65.20B | $65.20B |
| -Goodwill | $54.26B | $54.83B | $55.19B | $49.36B | $49.36B |
| -Other Intangible Assets | $18.08B | $18.61B | $19.15B | $15.84B | $15.84B |
| Other Non-Current Assets | $5.70B | $5.62B | $5.97B | $5.87B | $5.87B |
| Total Liabilities | $59.34B | $60.37B | $61.22B | $56.81B | $56.81B |
| Total Current Liabilities | $14.17B | $15.07B | $14.62B | $15.19B | $15.19B |
| Short-Term Debt and Capital Lease Obligation | $2.26B | $3.37B | $3.09B | $3.53B | $3.53B |
| -Current Debt | $2.26B | $3.37B | $3.09B | $3.53B | $3.53B |
| Other Current Liabilities | $11.91B | -$2.00M | – | – | – |
| Total Non-Current Liabilities | $45.17B | $45.30B | $46.60B | $41.62B | $41.62B |
| Long Term Debt and Capital Lease Obligation | $39.11B | $39.18B | $40.07B | $35.85B | $35.85B |
| -Long Term Debt | $39.11B | $39.18B | $40.07B | $35.85B | $35.85B |
| Other Non-Current Liabilities | $6.06B | $4.54B | $4.42B | $4.27B | $4.27B |
| Total Equity | $54.90B | $52.81B | $52.06B | $53.54B | $53.54B |
| Stockholders' Equity | $54.77B | $52.68B | $51.93B | $53.41B | $53.41B |
| Minority Interests | $128.00M | $128.00M | $128.00M | $129.00M | $129.00M |
| -Other Receivables | – | $1.69B | $1.68B | $1.67B | $1.67B |
| Payables | – | $3.27B | $3.34B | $3.62B | $3.62B |
| -Accounts Payable | – | $3.27B | $3.34B | $3.62B | $3.62B |
| Current Accrued Expenses | – | $5.52B | $5.26B | $5.32B | $5.32B |
| Current Deferred Liabilities | – | $2.92B | $2.93B | $2.71B | $2.71B |
| Non-Current Deferred Liabilities | – | $1.58B | $2.11B | $1.49B | $1.49B |
| Capital Stock | – | $446.00M | $445.00M | $445.00M | $445.00M |
| -Common Stock | – | $446.00M | $445.00M | $445.00M | $445.00M |
| -Preferred Stock | – | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | – | $18.87B | $18.71B | $18.56B | $18.56B |
| Retained Earnings | – | $62.19B | $60.63B | $59.16B | $59.16B |
| Less: Treasury Stock | – | $26.37B | $25.36B | $22.31B | $22.31B |
| Gains/Losses Not Affecting Retained Earnings | – | -$2.46B | -$2.50B | -$2.45B | -$2.45B |
| -Gross PPE | – | – | – | $18.38B | $18.38B |
| -Accumulated Depreciation | – | – | – | -$7.82B | -$7.82B |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.55B | $2.13B | $1.19B | $7.82B | $3.46B |
| Net cash flow from continuing operations | $2.55B | $2.12B | $1.19B | $7.82B | $3.46B |
| Net Income from Continuing Operations | $1.73B | $1.74B | $1.66B | $6.72B | $1.97B |
| Depreciation & Depletion & Amortization | $825.00M | $817.00M | $736.00M | $2.78B | $728.00M |
| Deferred Tax | -$210.00M | -$208.00M | -$258.00M | -$639.00M | $89.00M |
| Other Non-Cash Items | $416.00M | $118.00M | $87.00M | $412.00M | $97.00M |
| Change in Working Capital | -$43.00M | -$425.00M | -$1.11B | -$1.77B | $489.00M |
| Net cash flow from investing | -$77.00M | $164.00M | -$8.96B | -$4.05B | $891.00M |
| Net Cash Flow from Continuing Investing Activities | -$77.00M | $165.00M | -$8.96B | -$4.05B | $892.00M |
| Net PPE Purchase and Sale | -$436.00M | -$446.00M | -$367.00M | -$1.48B | -$438.00M |
| Net Business Purchase and Sale | $1.02B | $0.00 | -$8.87B | -$4.04B | $0.00 |
| Net Investment Purchase and Sale | -$629.00M | $554.00M | $332.00M | $1.45B | $1.33B |
| Net Other Investing Changes | -$28.00M | $56.00M | -$54.00M | $21.00M | $0.00 |
| Financing Cash Flow | -$1.06B | -$1.57B | $1.09B | $1.80B | $3.53B |
| Net Cash Flow from Continuing Financing Activities | -$1.06B | -$1.57B | $1.09B | $1.80B | $3.53B |
| Net Issuance Payments Of Debt | -$1.11B | -$389.00M | $4.22B | $5.35B | $3.63B |
| Net Common Stock Issuance | $0.00 | -$1.00B | -$3.00B | -$3.00B | -$37.00M |
| Cash Dividends Paid | -$174.00M | -$175.00M | -$162.00M | -$636.00M | -$162.00M |
| Net Other Financing Charges | $218.00M | -$7.00M | $40.00M | $90.00M | $91.00M |
| Ending Cash Balance | $5.49B | $4.10B | $3.28B | $9.88B | $9.88B |
| Net Change in Cash | $1.41B | $718.00M | -$6.68B | $5.57B | $7.87B |
| Beginning Cash Balance | $4.10B | $3.28B | $9.88B | $4.04B | $2.01B |
| Effect of Exchange Rate Changes | -$12.00M | $98.00M | $78.00M | $267.00M | -$6.00M |
| Free Cash Flow | $2.11B | $1.68B | $816.00M | $6.29B | $2.99B |
| -Change in Receivables | – | – | – | -$426.00M | – |
| -Change in Inventory | – | – | – | -$74.00M | – |
| -Change in Payables and Accrued Expense | – | – | – | $421.00M | – |
| -Change In Other Working Capital | – | – | – | -$1.69B | – |
No comments yet — be the first to weigh in on TMO.
Sign in to join the discussion.